Everywhere you look people are talking about peptides. But what exactly are they, how do they work and how safe are they for human consumption? Mike and Ross review the evidence, discuss the politics that continue to muddy the waters around peptide efficacy and regulation, and examine the dangers of using untested peptides. The team also look into the role of the popular GLP-1's that have revolutionised diabetes and weight loss and the controversial BPC-17 peptide, touted as a miracle treatment for tissue repair. LinksThe Undark article that describes the history of BPC157More on the FDA and the complex regulation of peptidesA report on one of the FDA decisions about peptides - in this case BPC157 and KPVA paper from the discoverer of BPC157, who has published more than three-quarters of the research on itThe human safety study on BPC157, with its two participantsSystematic review of BPC157 evidence, suggesting promise but cautionA well researched article by Dr Eric Topol raising concerns about safety and regulatory decisionsExample of a public warning from a regulatory body, this one from South AfricaFollow the money - Fortune 500 piece on why deregulation could create a multibillion dollar market Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related